| Revenue growth | Revenue +20% YoY, +6% QoQ to ₹1,560 Cr; broad-based. |
|---|---|
| Margins | EBITDA margin 21.6%: +19bps YoY, -131bps QoQ on input costs. |
| Demand visibility | Steady US controlled-substance demand; no volume guidance given. |
| Management confidence | Balanced-to-optimistic; deflects guidance and CDMO customer-win questions. |
Growth
Revenue +20% YoY and +6% QoQ, broad-based. PAT +39% YoY, but EBITDA +21% and gross margin down 134bps YoY.
Outlook
Five US launches planned in H2 FY27, two controlled substances. Genome Valley utilisation to cross 50% by Q4. No numeric revenue or margin guidance given.
Risks
Gagilapur warning letter unlifted with fresh 483 observations; ANDA approvals blocked. West Asia input and freight costs pressure margins. CDMO still loss-making; operating cash flow weak.
Earnings Call Transcript filed with NSE, NSE: GRANULES. Summary written with AI assistance from the document.
Granules India Ltd: key numbers
- Share price
- ₹821.95
- Market cap
- ₹20,368 Cr
- Revenue (annual)
- ₹5,366 Cr
- Net profit (annual)
- ₹595.0 Cr
- P/E (TTM)
- 30.8×Sector 45.9×
- Promoter holding
- 37.39%-0.63% QoQ
- FII holding
- 20.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Granules India Ltd
All →Granules India Other Announcement
Granules India submitted its monitoring agency report on preferential issue proceeds for quarter ended September 2026. It reports no deviation from stated objects.
Granules India Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹15,600 Mn (+20% YoY), EBITDA ₹3,376 Mn (21.6% margin), PAT ₹1,818 Mn (+39%). Net cash ₹8,280 Mn after warrant proceeds.
Granules India Results Update
Granules India reported Q2FY27 revenue of INR 15,600 Mn, up 20% YoY, and PAT of INR 1,818 Mn, up 39%. The company also cited a net cash position and a US FDA audit at its Gagillapur site.
Granules India Q2 FY27 Results: Net Profit ₹181.8 Cr, Up 39.2% YoY
Granules India Ltd reported revenue from operations of ₹1,560 Cr (+20.3% YoY) and net profit of ₹181.8 Cr (+39.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹181.8 Cr · +39.2% YoY
Granules India Business Update
Granules' Gagillapur facility received eleven USFDA observations with no impact on product supply. The inspection was the first since a February 2025 Warning Letter.
Granules India Convertible Warrants
Chigurupati family promoters disclosed acquiring 2,49,82,906 warrants via preferential allotment on 23 February 2026. Warrants priced at ₹585 each lift diluted promoter-group holding to 43.69%.
- Value
- ₹1,462 Cr